Tubular ACSM3 deficiency impairs medium-chain fatty acid metabolism and aggravates kidney fibrosis
Proceedings of the National Academy of Sciences · 23.09.2025 · 122 (38)
DOI: 10.1073/pnas.2505752122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 15.09.2025. Verfasst von Jinxi Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Institute of Kidney Diseases, West China Hospital of Sichuan University, Chengdu 610041, China. Hauptthemen laut MEDLINE: Fatty Acids, Coenzyme A Ligases, Kidney Tubules, Kidney Diseases. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MOST | National Natural Science Foundation of China (NSFC), SCU | West China Hospital, Sichuan University (WCH).
Abstract (Originalsprache)
Kidney fibrosis is driven by multiple factors, among which impaired fatty acid oxidation has emerged as a critical determinant. Acyl-Coenzyme A (CoA) synthetase medium-chain family member 3 (ACSM3), a key enzyme of medium-chain fatty acid (MCFA) metabolism, has been implicated in metabolic syndrome, but its function in fibrotic kidney remains unexplored. Here, we found that tubular epithelial ACSM3 expression was downregulated in kidney fibrotic mice and patients and inversely correlated with disease severity. Systemic and tubular-specific knockout of ACSM3 both exacerbated renal fibrosis, whereas adeno-associated virus (AAV)-mediated ACSM3 overexpression alleviated fibrotic kidneys in mice. Mechanistically, ACSM3 deficiency disrupted MCFA metabolism and resulted in abnormal mitochondrial homeostasis. Notably, we identified that dodecanoic acid (C12:0) could improve kidney fibrosis, which was primarily utilized via ACSM3 in kidneys. Furthermore, C12:0 oxidation impairment caused by tubular ACSM3 deficiency aggravated fibrotic kidney. Together, ACSM3-regulated MCFA metabolism played a pivotal role in kidney fibrosis, highlighting a potent drug target of ACSM3 and a potential supplementary therapy of MCFA against chronic kidney disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Institute of Kidney Diseases, West China Hospital of Sichuan University, Chengdu 610041, China.
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- SCU | West China Hospital, Sichuan University (WCH)
Zitieren
APA
Li, J., Xiang, T., Zhang, F., Feng, L., Wu, Y., Guo, F., Li, L., Fu, P., & Ma, L. (2025). Tubular ACSM3 deficiency impairs medium-chain fatty acid metabolism and aggravates kidney fibrosis. Proceedings of the National Academy of Sciences, 122(38). https://doi.org/10.1073/pnas.2505752122
Vancouver
Li J, Xiang T, Zhang F, Feng L, Wu Y, Guo F, et al. Tubular ACSM3 deficiency impairs medium-chain fatty acid metabolism and aggravates kidney fibrosis. Proceedings of the National Academy of Sciences. 2025;122(38). doi:10.1073/pnas.2505752122
BibTeX
@article{Li2025,
author = {Li, Jinxi and Xiang, Ting and Zhang, Fengping and Feng, Li and Wu, Yiting and Guo, Fan and Li, Lingzhi and Fu, Ping and Ma, Liang},
title = {Tubular ACSM3 deficiency impairs medium-chain fatty acid metabolism and aggravates kidney fibrosis},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
volume = {122},
number = {38},
doi = {10.1073/pnas.2505752122}
}
EUVIMED